Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

47 trials with published results (11%)

Research Maturity

165 completed trials (40% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.8%

20 terminated out of 413 trials

Success Rate

89.2%

+2.6% vs benchmark

Late-Stage Pipeline

6%

23 trials in Phase 3/4

Results Transparency

28%

47 of 165 completed with results

Key Signals

47 with results89% success20 terminated

Data Visualizations

Phase Distribution

255Total
Not Applicable (115)
Early P 1 (3)
P 1 (39)
P 2 (75)
P 3 (14)
P 4 (9)

Trial Status

Completed165
Recruiting86
Unknown74
Active Not Recruiting30
Not Yet Recruiting26
Terminated20

Trial Success Rate

89.2%

Benchmark: 86.6%

Based on 165 completed trials

Clinical Trials (413)

Showing 20 of 20 trials
NCT06991738Phase 1Not Yet RecruitingPrimary

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

NCT00001160Recruiting

Studies on Tumors of the Thyroid

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT04339478CompletedPrimary

Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection

NCT07428057Recruiting

Postoperative Hypocalcemia After Thyroidectomy

NCT03765333RecruitingPrimary

GETNE Registration of Thyroid Cancer

NCT06507878RecruitingPrimary

Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.

NCT04040673Withdrawn

RAman For Thyroid cancER

NCT04544111Phase 2Active Not RecruitingPrimary

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT07823439Not Yet Recruiting

Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals

NCT07822217Active Not RecruitingPrimary

Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered.

NCT07823543Not ApplicableNot Yet RecruitingPrimary

Educational Videos for Thyroid Surgery Patient

NCT05786924Phase 1Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT06796348Not ApplicableRecruitingPrimary

Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers

NCT04104529Not ApplicableRecruitingPrimary

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

NCT04285476Not ApplicableActive Not RecruitingPrimary

Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type

NCT01709292Phase 2Active Not RecruitingPrimary

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

NCT07707401Not ApplicableRecruiting

Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy

NCT07812779Not Yet Recruiting

Thyroid Health Outcomes Registry for Surgery

NCT05119296Phase 2Active Not RecruitingPrimary

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Scroll to load more

Research Network

Activity Timeline